• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharmaceuticals

Tax holiday could ignite more pharma M&A

December 6, 2016 By Sarah Faulkner

Capitol Hill

(Reuters) – U.S. President-elect Donald Trump’s plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth. For years, big U.S. drugmakers have turned to acquisitions of foreign companies to put their overseas cash to work, […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Amgen, Apple, Biogen Idec, Bristol-Myers Squibb Co., Eli Lilly & Co., Gilead Sciences, johnsonandjohnson, Pfizer Inc.

Novo Nordisk joins Allergan in pledge to limit price hikes

December 6, 2016 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) president Jakob Riis said this week that the company will limit annual price hikes of its products’ list prices to single-digit percentages, joining Allergan (NYSE:AGN) CEO Brent Saunders who released a “social contract” 3 months ago with the same goal. “We hear from more and more people living with diabetes about the challenges […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Mylan, Novo Nordisk

Sanofi throws hat in the ring with J&J’s in Actelion pursuit

December 6, 2016 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Pfizer Inc., Roche, Sanofi-Aventis

Scilex touts data for novel lidocaine patch

December 5, 2016 By Sarah Faulkner

Scilex Pharmaceuticals

Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that its lidocaine patch, ZTlido, met primary and secondary endpoints in a pivotal study comparing the patch to Endo Pharmaceutical‘s Lidoderm patch. The data will be used to resubmit a new drug application to the FDA in mid-2017, the Malvern, Pa.-based company said. The clinical trial evaluated Scilex’s […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals, Scilex Pharmaceuticals, Sorrento Therapeutics

GSK, Innoviva seek EU nod for triple combo inhaled therapy

December 5, 2016 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said last week that they filed a regulatory submission with the European Medicines Agency for the once-daily, triple-combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. Last month, the companies submitted a new drug application for the inhaled therapy to the FDA for approval in the U.S. The triple combination therapy is […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Innoviva

Pharma execs assess landscape under President Trump

December 2, 2016 By Sarah Faulkner

capitol hill

Executives from U.S. drugmakers such as Regeneron Pharmaceuticals and Pfizer talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week. After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal […]

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc., Regeneron

Hedge funds betting on J&J after Actelion remains silent on takeover bid

December 2, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Despite reports this week that Actelion Pharmaceuticals (VTX:ATLN) rejected Johnson & Johson‘s (NYSE:JNJ) 2nd takeover bid, hedge funds are piling into the Swiss biotech firm, encouraged by Actelion’s silence on the matter. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Mylan CEO Bresch accepts “full responsibility” for EpiPen price hikes

December 2, 2016 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) CEO Heather Bresch reportedly accepted “full responsibility” for the company’s EpiPen price hikes that sparked outrage over the past 2 months, but defended the company’s actions while blaming an opaque industry that she said was not built for consumer engagement. The CEO made her remarks at the Forbes Healthcare Summit in New York on Thursday. “There are […]

Filed Under: Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Merck, Mylan

Impel NeuroPharma closes $36m series C round for intranasal CNS treatments

December 2, 2016 By Sarah Faulkner

Impel NeuroPharma

Impel NeuroPharma Inc. said today that it closed a $36 million series C financing round to fund its pipeline of precision olfactory delivery (POD) intranasal devices. Life science firms venBIO, 5AM Ventures and Vivo Capital made investments in the round. Seattle-based Impel will get $21 million upfront and $15 million after it reaches development and […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

Modification to delivery polymer sidesteps allergic response

December 1, 2016 By Sarah Faulkner

Researchers from Duke University have reconfigured the popular drug-delivery polymer, polyethylene glycol, to sidestep dangerous immune responses that have previously halted clinical trials. The team’s work was published in Nature Biomedical Engineering. Polyethylene glycol, PEG, is a polymer that is found in toothpaste and cosmetics, but is often used in pharmaceuticals. It can be attached to […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Duke University

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 199
  • Page 200
  • Page 201
  • Page 202
  • Page 203
  • Interim pages omitted …
  • Page 206
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS